Compare WNW & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNW | JAGX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.9M |
| IPO Year | 2019 | 2014 |
| Metric | WNW | JAGX |
|---|---|---|
| Price | $2.37 | $3.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.5K | ★ 3.1M |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $77.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.05 | $0.20 |
| 52 Week High | $13.52 | $41.53 |
| Indicator | WNW | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 49.80 |
| Support Level | $2.30 | $0.89 |
| Resistance Level | $2.75 | $8.00 |
| Average True Range (ATR) | 0.13 | 4.48 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 8.13 | 10.26 |
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.